ProvexCV

For several years now, ProvexCV's combination of heart-healthy ingredients, including grape seed, grape skin, quercetin, bilberry, ginkgo biloba, and its exclusive enzyme blend has helped

(1) reduce LDL ("bad") cholesterol oxidation in the bloodstream and
(2) inhibit blood platelet aggregation—two of the leading causes of heart disease.

Since the 1990s, Melaleuca's in-house team has led the effort in partnership with Dr. John Folts, a renowned cardiovascular researcher at the University of Wisconsin. Among his many accomplishments, Dr. Folts is credited with being the first to document the positive effect of aspirin on arterial blood clotting. With aspirin, it took 20 years from the time Dr. Folts discovered and documented the impact it has on platelet activity before the Bayer Company could make the heart-health claim on their label.

The development of ProvexCV has been a thorough process, involving live-human testing and measurement, requiring months of effort to document and analyze the research data. Traveling the globe, Melaleuca scientists have found that different strains of grapes provided widely varying levels of flavonoid activity, particularly in regards toa group of flavonoids known as proanthocyanidins. Certain proanthocyanidins have been found to be 10 times more powerful than vitamin E in antioxidant activity, and Melaleuca has protected its right to the best sources on the market.